Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma

Transarterial chemoembolization (TACE) is a widely used standard treatment for patients with hepatocellular carcinoma (HCC) who are not suitable candidates for curative treatments. The rationale for TACE is that intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by sele...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG Vol. 22; no. 40; p. 8853
Main Authors: Nam, Hee Chul, Jang, Bohyun, Song, Myeong Jun
Format: Journal Article
Language:English
Published: United States 28.10.2016
Subjects:
Antibiotics, Antineoplastic - administration & dosage
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - therapy
Chemoembolization, Therapeutic
Cost-Benefit Analysis
Doxorubicin - administration & dosage
Humans
Liver Neoplasms - mortality
Liver Neoplasms - therapy
Outcome Assessment (Health Care)
Hepatocellular carcinoma
Treatment response
Drug-eluting beads
Transarterial chemoembolization
Conventional TACE
ISSN:2219-2840, 2219-2840
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transarterial chemoembolization (TACE) is a widely used standard treatment for patients with hepatocellular carcinoma (HCC) who are not suitable candidates for curative treatments. The rationale for TACE is that intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, results in a strong cytotoxic effect as well as ischemia (conventional TACE). Recently, drug-eluting beads (DC Beads ) have been developed for transcatheter treatment of HCC to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor. DC Beads can actively sequester doxorubicin hydrochloride from solution and release it in a controlled sustained fashion. Treatment with DC Beads substantially reduced the amount of chemotherapeutic agent that reached the systemic circulation compared with conventional, lipiodol-based regimens, significantly reducing drug-related adverse events. In this article, we describe the treatment response, survival, and safety of TACE used with drug-eluting beads for the treatment of HCC and discuss future therapeutic possibilities.
Bibliography:SourceType-Scholarly Journals-1
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:2219-2840
2219-2840
DOI:10.3748/wjg.v22.i40.8853